GlassScriptPhysician profile
Nima Rezaei Abbassi
NPI 1851619407
$1,660.37
in general payments reported to CMS, 2019-2025
15 companies · $24.55 in 2025
The $24.55 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $577 · 2021: $345 · 2022: $275 · 2023: $62.94 · 2024: $20.55 · 2025: $24.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $108.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $331.64 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $327.47 | 2019-2021 | |
| Alcon Vision LLC | $285.69 | 2019-2025 | Clareon, Rocklatan |
| Mallinckrodt Hospital Products INC. | $187.91 | 2021-2022 | |
| Glaukos Corporation | $170.27 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $93.66 | 2019-2020 | |
| Sight Sciences, INC. | $71.87 | 2022-2023 | Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $50.76 | 2019-2020 | |
| Dompe US, INC. | $33.24 | 2021 | |
| Dentsply Sirona INC | $22.10 | 2019 | |
| Boston Scientific Corporation | $20.55 | 2024 | |
| Oyster Point Pharma, INC. | $19.73 | 2022 | |
| Horizon Therapeutics Plc | $19.01 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.67 | 2021 | |
| Abbvie INC. | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nima Rezaei Abbassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.